Market Research Reports and Industry Reports

Therapeutic Class Report Overview - Rituxan Biosimilar

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roches/Biogen Idecs Rituxan/MabThera (rituximab), Merck and JNJs Remicade (infliximab), and Amgen and Pfizers Enbrel (etanercept) had WW sales of ~$23b in 2011 and have patents expiring in EU and ROW in 2013/14. Biosimilar version of Rituxan was launched by Dr Reddys Lab. (DRL), Reditux, in India in 2007 and many others are in the pipeline targeting EU, ROW market; Roche is deploying life-cycle management strategies to protect its Rituximab franchise, which despite competition continues to have a healthy growth rate.

In this report, we have analyzed the market opportunity of Rituximab Biosimilar and its competitive landscape. We believe that despite several clinical setbacks in the Rituxan biosimilars pipeline, they could pose a challenge to Rituximab by 2018.
N/A

List Of Tables

N/A

List Of Figures

N/A

United States Proliferative Diabetic Retinopathy Therapeutics Market Report 2017

In this report, the United States Proliferative Diabetic Retinopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

United States Retinopathy Of Prematurity Therapeutics Market Report 2017

In this report, the United States Retinopathy Of Prematurity Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

Therapeutic Class Report Overview - Future Of GPR Agonist

Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening

USD 1000View Report

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations

USD 1000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprisewide Licence    USD 6000
$ 2000

Reports Details

Published Date : Feb 2013
No. of Pages :45
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube